These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
309 related articles for article (PubMed ID: 37989956)
1. Educational Review: Clinical Application of Immune Checkpoint Blockade for the Treatment of Melanoma. Su D; Kluger H; Olino K Ann Surg Oncol; 2024 Mar; 31(3):1865-1879. PubMed ID: 37989956 [TBL] [Abstract][Full Text] [Related]
2. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
4. The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review. Moujaess E; Haddad FG; Eid R; Kourie HR Immunotherapy; 2019 Nov; 11(16):1409-1422. PubMed ID: 31621445 [TBL] [Abstract][Full Text] [Related]
5. Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma. Carreau NA; Pavlick AC Future Oncol; 2019 Feb; 15(4):349-358. PubMed ID: 30334646 [TBL] [Abstract][Full Text] [Related]
6. Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update. Kähler KC; Hassel JC; Heinzerling L; Loquai C; Thoms KM; Ugurel S; Zimmer L; Gutzmer R; J Dtsch Dermatol Ges; 2020 Jun; 18(6):582-609. PubMed ID: 32489011 [TBL] [Abstract][Full Text] [Related]
7. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders. Brown LJ; Weppler A; Bhave P; Allayous C; Patrinely JR; Ott P; Sandhu S; Haydon A; Lebbe C; Johnson DB; Long GV; Menzies AA; Carlino MS J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963010 [TBL] [Abstract][Full Text] [Related]
8. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Buchbinder EI; Desai A Am J Clin Oncol; 2016 Feb; 39(1):98-106. PubMed ID: 26558876 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials. Hao C; Tian J; Liu H; Li F; Niu H; Zhu B Medicine (Baltimore); 2017 Jun; 96(26):e7325. PubMed ID: 28658143 [TBL] [Abstract][Full Text] [Related]
11. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma. Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905 [TBL] [Abstract][Full Text] [Related]
12. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis. Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531 [TBL] [Abstract][Full Text] [Related]
13. Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade. Bello DM; Panageas KS; Hollmann T; Shoushtari AN; Momtaz P; Chapman PB; Postow MA; Callahan MK; Wolchok JD; Brady MS; Coit DG; Ariyan CE Ann Surg Oncol; 2020 Apr; 27(4):1180-1188. PubMed ID: 31848819 [TBL] [Abstract][Full Text] [Related]
15. Nivolumab Plus Relatlimab: First Approval. Paik J Drugs; 2022 Jun; 82(8):925-931. PubMed ID: 35543970 [TBL] [Abstract][Full Text] [Related]
16. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents. Weber JS; Postow M; Lao CD; Schadendorf D Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894 [TBL] [Abstract][Full Text] [Related]
17. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Ott PA; Hodi FS; Robert C Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443 [TBL] [Abstract][Full Text] [Related]
18. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient. Herz S; Höfer T; Papapanagiotou M; Leyh JC; Meyenburg S; Schadendorf D; Ugurel S; Roesch A; Livingstone E; Schilling B; Franklin C Eur J Cancer; 2016 Nov; 67():66-72. PubMed ID: 27614165 [TBL] [Abstract][Full Text] [Related]
19. The role of nivolumab in melanoma. Gomes F; Serra-Bellver P; Lorigan P Future Oncol; 2018 Jun; 14(13):1241-1252. PubMed ID: 29328782 [TBL] [Abstract][Full Text] [Related]